Study S000334

The Impact of Pramlintide on Top of Semaglutide in Obese People With Prediabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06619015
Acronym: TOTT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: TRIPLE
Status: WITHDRAWN
Enrollment: 0
Start: 2025-04-01
Primary completion: 2025-04-01
Lead sponsor: Esbjerg Hospital - University Hospital of Southern Denmark
Conditions: Obesity; Appetite Regulation; PreDiabetes
Interventions: DRUG:Pramlintide Acetate 1 MG/ML; DRUG:Semaglutide Pen Injector; DRUG:Sodium Chloride 0.9% Inj
Results posted: FALSE
Secondary identifiers: CTIS:2024-510802-10-00

Registered primary outcomes

Change in kilocalorie (kCal) consumption at ad libitum meal test, from baseline, to after 26 weeks of semaglutide of which the last two weeks is with the addition of either pramlintide or placebo [From baseline at the start of the study(week 0), to the end of the study after 26 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.